New! Sign up for our free email newsletter.
Science News
from research organizations

Promising target for treating brain tumors in children

Drug shrinks tumor, increases survival in animal model

Date:
November 30, 2017
Source:
Ann & Robert H. Lurie Children's Hospital of Chicago
Summary:
Research offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro.
Share:
FULL STORY

Findings published in Oncotarget offer new hope for children with highly aggressive brain tumors like atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma. Previously, the authors of the study have shown that an experimental drug that inhibits polo-like kinase 4 (PLK4) stopped pediatric brain tumor growth in vitro. Now, they have demonstrated its success in an animal model -- the drug shrank the tumor and increased survival. Importantly, the PLK4 inhibitor was able to cross the blood-brain barrier, which means that the drug can target cancer cells in the brain even when taken orally, avoiding the need for injection into the spinal fluid. In this new study, researchers also demonstrated that when they associate a PLK4 inhibitor with traditional chemotherapy drugs, they kill tumor cells with significantly lower drug doses.

"We are very excited with the outcome of this work," said lead author Simone Treiger Sredni, MD, PhD, Associate Professor of Pediatric Neurosurgery at Northwestern University Feinberg School of Medicine and cancer researcher at the Stanley Manne Children's Research Institute of Ann & Robert H. Lurie Children's Hospital of Chicago. "This promising treatment strategy may also help us reduce toxicity when used with other chemotherapy agents."

In a previous study, Sredni and colleagues were the first to describe PLK4 as a therapeutic target for brain tumors and in pediatric cancer. They found that, in these particular types of tumors, PLK4 regulates tumor growth and the tumor's tendency to metastasize.

AT/RT is a therapy resistant brain tumor that mostly occurs in infants. Medulloblastoma is the most frequent malignant brain tumor in children and current treatments for it are highly toxic. Both of these types of brain tumors have a high mortality rate.

"New targeted therapies are urgently needed for children with AT/RT and medulloblastoma," said Sredni. "We expect that targeting PLK4 will prove to be an effective and less toxic treatment approach for these children, and we hope to move to a clinical trial soon."


Story Source:

Materials provided by Ann & Robert H. Lurie Children's Hospital of Chicago. Note: Content may be edited for style and length.


Journal Reference:

  1. Simone Treiger Sredni, Anders W. Bailey, Amreena Suri Bsc, Rintaro Hashizume, Xingyao He, Nundia Louis, Tufan Gokimak, David R. Piper, Daniel M. Watterson, Tadanori Tomita. Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma. Oncotarget, 2017; DOI: 10.18632/oncotarget.22704

Cite This Page:

Ann & Robert H. Lurie Children's Hospital of Chicago. "Promising target for treating brain tumors in children." ScienceDaily. ScienceDaily, 30 November 2017. <www.sciencedaily.com/releases/2017/11/171130122858.htm>.
Ann & Robert H. Lurie Children's Hospital of Chicago. (2017, November 30). Promising target for treating brain tumors in children. ScienceDaily. Retrieved March 29, 2024 from www.sciencedaily.com/releases/2017/11/171130122858.htm
Ann & Robert H. Lurie Children's Hospital of Chicago. "Promising target for treating brain tumors in children." ScienceDaily. www.sciencedaily.com/releases/2017/11/171130122858.htm (accessed March 29, 2024).

Explore More

from ScienceDaily

RELATED STORIES